Clonal deletion in the thymus by apoptosis is involved in purging the immune system of self-reactive T lymphocytes (negative selection). Cysteine proteases (caspases) belonging to the CPP32 family are activated during this process. We have produced transgenic mice expressing baculovirus p35, a broad-range caspase inhibitor. Thymocytes from p35 transgenic mice were resistant in vitro to several apoptosis-inducing agents; this resistance correlated with the inhibition of CPP32-like activity. Negative selection in vivo of thymocytes triggered by two exogenous antigens, staphylococcal enterotoxin B superantigen and an antigenic peptide in the F5 T-cell receptor transgenic model, was specifically inhibited in p35 transgenic mice. Our results provide direct evidence for caspase involvement in negative selection during thymocyte development.
Introduction
Apoptosis (programmed cell death) is a basic feature and an evolutionarily conserved mechanism in the development and homeostasis of the immune system (Nagata, 1997) . Developing B and T lymphocytes that do not express functional antigen receptor fail to receive a positive signal and die via apoptosis (death by neglect), whereas lymphocytes bearing self-reactive antigen receptors undergo apoptosis in response to a death signal from neighboring cells (negative selection). Negative selection for thymocytes requires T-cell receptor (TCR)-mediated recognition of antigenic peptides associated with major histocompatibility complex (MHC) class I or II molecules on the surface of antigen-presenting cells (APC), and involves thymocytes at the immature CD4 ϩ /CD8 ϩ double positive (DP) development stage or early in the mature single positive (SP) stage (Nossal, 1994; Sprent and Webb, 1995) .
Caspases or cysteine proteases of the interleukin-1β converting enzyme (ICE) family are common, essential mediators of diverse cell-death processes (Nicholson and Thornberry, 1997) . Recent evidence demonstrates that caspase activation is involved in TCR-induced cell death 156 © European Molecular Biology Organization of thymocytes in vitro (Alam et al., 1997; Clayton et al., 1997) , but there is no formal evidence for caspase involvement in negative selection in vivo. There are currently 10 members of the human caspase family (Nagata, 1997) , which exist as proenzymes and are activated when cleaved into subunits of 17-20 and 10-12 kDa. The molecular structures of ICE (caspase-1) and CPP32 (caspase-3) have been established; structural comparison suggests that the caspases can be divided into two major groups: those resembling caspase-1 (ICE family) and those resembling caspase-3 (CPP32-like family) (Clayton et al., 1997) , which correspond functionally to 'initiator' and 'effector' caspases, respectively Villa et al., 1997) . The hierarchy of these initiators and effectors is best known for CD95 and tumor necrosis factor-R (TNF-R), but remains controversial as a whole. Receptor ligation leads to activation by recruitment of initiator caspases (caspases-8 and -10) via adapter molecules such as FADD/MORT-1 (Boldin et al., 1996; Muzio et al., 1996) . Activation of these caspases in turn activates, directly or indirectly, the effector caspases (caspases-3, -6 and -7). Activation of effector caspases is thought to induce proteolysis of a wide variety of protein substrates involved in DNA repair, homeostatic and structural functions, whose cleavage collectively constitutes the apoptotic phenotype (Nicholson and Thornberry, 1997) .
Various biological approaches have been used to study the role of different caspases and their function in negative selection. Gene knockout approaches have demonstrated the difficulty of analyzing the role of specific caspases on negative selection and thymocyte apoptosis, probably due to redundancy among caspase family members and the complexity of their interactions. In particular, caspase-1 (ICE) knockout (KO) mice show that caspase-1 does not appear to play an important, non-redundant role in thymocyte apoptosis and thymic development. Despite in vitro resistance of caspase-1 -/-thymocytes to anti-CD95-induced cell death, the caspase-1 KO has no effect on negative selection (Kuida et al., 1995) . Similarly, the caspase-3 (CPP32) KO shows no differences in thymocyte apoptosis induced in vitro by several agents (anti-TCR/ CD3, anti-CD95, dexamethasone, ceramide), and thymocyte development occurs normally (Kuida et al., 1996) . Thymocytes and T lymphoblasts from caspase-2 KO mice are as sensitive in vitro as wild-type cells to anti-CD95, γ-irradiation or DNA-damaging agents (Bergeron et al., 1998) . Caspase-9-deficient thymocytes display normal cell death to TNFα, anti-CD95 and UV light, but are resistant to dexamethasone (Dex) and γ-irradiation (Hakem et al., 1998; Kuida et al., 1998) . Single KO models thus suggest that redundancy between caspases is a general feature, rather than an exception, in thymocyte apoptosis (Nicholson and Thornberry, 1997) .
Specific caspase inhibitors have been widely used both in fetal thymic organ cultures (FTOC) and in transgenic (tg) models (Nicholson and Thornberry, 1997; Villa et al., 1997) . Small caspase peptide inhibitors efficiently inhibit anti-TCR, anti-CD95 or Dex-induced thymocyte apoptosis in FTOC (Alam et al., 1997; Clayton et al., 1997; Villa et al., 1997) . These peptides cannot be assumed to inhibit caspase family members selectively, in particular when intracellular inhibitor concentrations cannot be measured (Villa et al., 1997) . In addition, prolonged incubation times of whole cells can diminish any specificity they might have. Although transgenic expression of cytokine response modifier A (crmA), a viral specific caspase-1 (ICE) inhibitor, inhibits anti-CD95-induced thymocyte cell death in vitro, it does not affect negative selection (Smith et al., 1996) . A second viral caspase inhibitor has been described; this inhibitor, baculovirus p35, appears to block cells from undergoing an apoptotic response to viral infection (Bump et al., 1995) . Although it has no significant similarity to crmA, p35 also exerts its protective effect by irreversible competitive inhibition (Bertin et al., 1996) . In contrast to crmA, which inhibits only caspases-1 and -8, but not effector caspases of the CPP32-like family (Villa et al., 1997; Zhou et al., 1997) , p35 inhibits caspases-1, -2, -3, -4, -6, -7, -8 and -10 in vitro (Bump et al., 1995; Ahmad et al., 1997; Zhou et al., 1998) . p35 blocks apoptosis induced by TNF-R or CD95 ligation, glucocorticoids, ceramides, ionizing radiation, DNA-damaging agents, nerve growth factor withdrawal; it also inhibits cell death in Drosophila via death proteins including the products of reaper, hid, grim and Doom genes, as well as normal developmental death in both Caenorhabditis elegans and Drosophila melanogaster. Therefore, p35 has a broader spectrum of death-pathway inhibition than crmA (Villa et al., 1997) .
Thymocyte negative selection is not perturbed in mutant mice lacking a single caspase family member or in tg mice expressing a restricted caspase inhibitor such as crmA, presumably due to functional redundancy among caspase family members. This prompted us to generate p35 tg mice, which allowed us to study the impact of this broad-spectrum cell-death inhibitor on thymocytes in vitro and in vivo. Here we show inhibition of antigen-induced negative selection in p35 tg mice, providing evidence for caspase involvement in this process.
Results
p56lck pr -p35 transgenic mice Transgenic mice were generated expressing the Autographa californica nucleopolyhedrovirus p35 (Acp35) gene under the control of the p56lck proximal promoter (p56lck pr ). This promoter has been used widely to trigger thymocyte-restricted transgene expression; the promoter is most active in immature cells and almost silent in mature peripheral T lymphocytes (Wildin et al., 1991) . The transgenic construct was generated by inserting 1 kb Acp35 cDNA into the BamHI site of the p1017 vector (Chaffin et al., 1990) , which includes a 3.2 kb fragment of the lck proximal promoter (p56lck pr ), the 1 kb Acp35 insert 3Ј downstream and a 2.1 kb genomic hGH sequence. A 6.3 kb NotI-linearized vector was injected into (C57BL/ 6ϫCBA/J)F 1 embryos by standard techniques; 12 founder mice were generated and identified by PCR-based screening.
Three independent murine lines were generated by backcrossing founders with C57BL6/J mice, giving rise to mice with low (1-2), intermediate (~10), and high (~20) transgene copy numbers, as established by quantitation of Southern blot analysis ( Figure 1A ). Mice from intermediate and high copy number lines showed a similar phenotype; here we report observations in two independent transgenic lines, #2 and #19, with intermediate and high copy numbers, respectively. Transgene expression was analyzed by Western blot with p35-specific polyclonal antisera. The two transgenic lines showed comparable thymic p35 protein expression ( Figure 1B ), but none was detected in other lymphoid organs such as spleen or lymph nodes ( Figure 1C ). This distribution may reflect the fact that the promoter is more active in immature thymocytes than in mature thymocytes and peripheral T cells (Wildin et al., 1991) . Accordingly, interleukin-2 (IL-2)-dependent T lymphoblasts from mitogen-stimulated transgenic splenocytes or thymocytes expressed no detectable p35 protein (see below).
The thymus, spleen and lymph nodes of p56lck pr -p35 tg mice were normal in size and histological appearance, and no perturbations of lymphocyte populations were observed by flow-cytometric analysis using antibodies to CD2, CD3, CD4, CD5, CD8, IgM, B220, TCRVβ8, CD25, CD44 and CD95 (not shown). Expression of the p35 general caspase inhibitor thus did not grossly perturb T lymphocyte development or homeostasis.
Functional inactivation of effector caspases and inhibition of in vitro thymocyte apoptosis by p35 expression Baculovirus p35 effectively inhibits caspases-1, -2, -3, -4, -6, -7, -8 and -10 in vitro (Bump et al., 1995; Ahmad et al., 1997; Villa et al., 1997; Zhou et al., 1998) and also blocks apoptosis induced by a wide variety of agents in cycling cell lines from mammals, insects and nematodes Salvesen and Dixit, 1997; Villa et al., 1997) . Caspase-3 (CPP32-like) family effector caspases are essential, conserved components of the apoptotic machinery in many cell types and have been implicated in thymocyte apoptosis (Alam et al., 1997) . To test the functional expression of the transgene, we analyzed the ability of CD95 to trigger activation of effector caspase-3-like activity in thymocytes from p35 tg mice and wild-type littermates. Caspase-3-like activity was assessed as hydrolysis of a specific fluorescent peptide substrate. Anti-CD95 antibody induced transient activation of caspase-3-like activity (5-to 10-fold) that peaked~3-4 h after stimulus addition (Figure 2 ). p35 expression completely abrogated anti-CD95-induced caspase-3-like activation. Basal (unstimulated) CPP32-like activity was also reduced in p35 transgenic thymocytes (Figure 2) . p35 caspase inhibitor expression may inhibit apoptosis caused by death domain-containing receptors of the TNF-R family and other apoptosis inducers. To test this, thymocytes from p35 tg mice and control littermates were compared for susceptibility to cell-death induction by in vitro culture (spontaneous cell death) or treatment with anti-CD95 antibody. Thymocytes in the sub-G 0 /G 1 cell- Fig. 2 . Expression of p35 protein inhibits anti-CD95-induced caspase-3-like activation. Thymocytes (4ϫ10 6 cells/ml) from two control wildtype littermates (Nos 1 and 6) or two p35 tg mice (Nos 7 and 8) were treated with anti-CD95 antibody JO2 (1 μg/ml) or left untreated (spontaneous cell death). After culture, cells were lysed and extracts assayed for caspase activity using a fluorogenic substrate as indicated in Materials and methods. This activation was fully inhibited when Ac-DEVD-CHO, a specific peptide inhibitor of this caspase family, was added to the extract, demonstrating the specificity of this assay for the caspase-3-like family. Results are expressed as mean Ϯ SD of fluorescence in arbitrary units (AU) for duplicate samples.
cycle phase were analyzed using propidium iodide (PI) to evaluate the percentage of cell death at different time points. p35 transgene expression caused very weak but consistent inhibition of spontaneous thymocyte cell death ( Figure 3A and C). p35 tg thymocytes were resistant to apoptosis via ligation of CD95 ( Figure 3A ). Kinetic analysis of anti-CD95-induced cell death demonstrated intrinsic resistance of p35 thymocytes to anti-CD95 doses ranging from 0.1 to 5 μg/ml throughout the 60 h time course ( Figure 3A and data not shown). Compared with untreated thymocytes, cell survival at 60 h after anti-CD95 treatment was 25% in wild-type thymocytes, whereas survival was~80% in p35 thymocytes. This resistance to anti-CD95-induced apoptosis was not due to lower CD95 levels in p35 thymocytes (not shown). This resistance resembles that seen in thymocytes from lpr/lpr (spontaneous CD95 null) or CD95 KO mice at the same time point (Takahashi et al., 1994; Adachi et al., 1995 Adachi et al., , 1996 Ogasawara et al., 1995) . These results show that p35 prevents CD95-transduced apoptosis in freshly isolated, non-cycling cells.
We studied the consequences of p35 expression on thymocyte apoptosis induced via the TNFα receptor and the TCR, as well as by a variety of apoptosis inducers such as genotoxins (etoposide, hydroxyurea), UV light, Dex and ceramide (Nicholson and Thornberry, 1997) . p35 thymocytes displayed a small, but significant, resistance to Dex and UV light-induced cell death; comparable effects were obtained when DNA-damaging agents such as etoposide and hydroxyurea were used to trigger cell death ( Figure 3B ). After exposure to TNFα, anti-TCR or C2-ceramide, we observed partial inhibition of apoptosis in p35 transgenic thymocytes at later time points (60 h) ( Figure 3C ). These effects correlated with the ability of p35 to inhibit the caspase-3-like activation induced by these stimuli (not shown). This general inhibitory effect on apoptosis was due to p35 protein expression and not to a non-specific effect produced by transgene integration, since (i) comparable results were observed in the two independent transgenic lines, and (ii) IL-2-dependent Tcell blasts from mitogen-stimulated p35 tg thymocytes and splenocytes, which did not detectably express the transgene, displayed unaffected apoptosis and activationinduced cell death (Figure 4 ). In in vitro assays, therefore, Fig. 3 . p35 inhibits in vitro apoptosis of thymocytes. Thymocytes (4ϫ10 6 cells/ml) from control wild-type littermates (Nos 1 and 6) or p35 tg mice (Nos 7 and 8) were treated with anti-CD95 JO2 antibody (1 μg/ml) or untreated (spontaneous cell death) for the culture periods indicated (A), or treated with Dex (100 nM), exposed to UV light (10 mJ/cm 2 ), treated with etoposide (1.6 μg/ml) or hydroxyurea (1 mM) (B). Thymocytes (4ϫ10 6 cells/ml) from control wild-type littermates (Nos 16 and 23) or p35 tg mice (Nos 21 and 22) were untreated (spontaneous cell death) or treated with mTNFα (1000 U/ml), anti-CD3ε (TCR agonist, 10 μg/ml-coated wells) or C2-ceramide (10 μM) (C). Viable (diploid) cells were quantitated by cell-cycle analysis with PI staining. The values depict the percentage of diploid cells in treated cultures compared with that of untreated cultures (spontaneous cell death). Results are representative of the data obtained in four independent experiments. SD bars were not included to aid in visualizing the data, but the SD was Ͻ5% in all cases.
p35 thymocytes showed high-to-moderate resistance to the diverse apoptotic stimuli tested.
Spontaneous thymocyte death involves a p35-and AcDEVD-CHO-insensitive caspase
Although p35 expression in thymocytes conferred resistance to several apoptosis inducers in vitro, spontaneous cell death in culture was unaffected. This cell death could be a non-apoptotic process independent of caspase activation, which would make it insensitive to a caspase inhibitor such as p35. To rule out this possibility, we analyzed spontaneous thymocyte death in the presence of two widely used caspase inhibitors, Z-Val-Ala-DL-Aspfluoromethylketone (zVAD-fmk) and Ac-Asp-Glu-Valaspartic acid aldehyde (AcDEVD-CHO). zVAD-fmk is a general caspase inhibitor, whereas AcDEVD-CHO inhibits mainly caspases-3 and -7 (Longthorne and Williams, 1997) . zVAD-fmk (10 μM) efficiently inhibited spontaneous cell death in both wild-type and p35 transgenic thymocytes throughout the time course, and AcDEVD-CHO (100 μM) was unable to block cell death ( Figure  5A ). The effects observed were not due to differential cell permeability of these inhibitors, since both effectively inhibited CPP32-like (DEVD-cleaving) activity in thymocyte lysates ( Figure 5B) . These results also demonstrate the presence of DEVD-cleaving caspase activity in these lysates prior to cell loss of viability. This caspase is not involved in spontaneous cell death, since when it is completely inhibited in p35 thymocytes, significant cell death still occurred in these cells ( Figure 5A and B). p35 (B) T lymphoblasts were prepared by culturing thymocytes from control littermates (Nos 1 and 6) and p35 tg mice (Nos 7 and 8) in PMA (2 ng/ml) and ionomycin (1 μg/ml) for 3 days. Cells (1ϫ10 6 /ml) were then cultured in IL-2-conditioned medium for 3 days. In some experiments, cells were deprived of IL-2 to analyze growth factor deprivation-induced apoptosis ]. In other cases, activation-induced apoptosis (anti-CD3ε-coated plates, TCR) was assessed in the presence of IL-2. Apoptosis was also induced with hydroxyurea (1 mM) or UV light (10 mJ/cm 2 ) in the presence of IL-2. Cell-cycle analysis was performed after 24 h. The values depict the percentage of surviving cells (G 0 /G 1 , S and M phases of the cell cycle) maintained in culture with IL-2 (medium) or deprived/treated cells. Results are representative of three different experiments.
expression was as effective as the small peptide inhibitors in terms of CPP32-like activation. The spontaneous cell death therefore involves activation of a caspase(s) inhibitable by zVAD-fmk, but not by p35 or p35 plus AcDEVD-CHO. Spontaneous cell death was also associated with CPP32 cleavage ( Figure 5C ) and poly(ADPribose) polymerase (PARP) processing ( Figure 5D ), which was delayed but not abrogated in p35 transgenic thymocytes. In summary, a caspase(s) activity responsible for CPP32 processing and which exhibits PARP-cleaving activity is involved in spontaneous thymocyte cell death. This caspase is not a target for p35 or the AcDEVD-CHO caspase inhibitor. 5 . A p35-insensitive caspase is involved in spontaneous thymocyte cell death. Thymocytes (4ϫ10 6 /ml) from a wild-type mouse and a p35 tg mouse were cultured at 37°C in the absence (dimethyl sulfoxide control) or presence of zVAD-fmk (10 μM) and AcDEVD-CHO (100 μM). At the times indicated, samples were removed for cell-cycle analysis (A) and assessment of DEVD-cleaving activity (B) in cell lysates. In some experiments, Western blotting was performed with whole-cell lysates to determine spontaneous CPP32 processing (C) and PARP cleavage (D), as described in Materials and methods. Lysates of A20 B cells treated for 1 h with anti-CD95 were included as a control, shown at the right in both panels. Arrows indicate the processed forms of both proteins. Results are representative of the data obtained in three different experiments. SD bars were not included in line graphics to aid in visualizing the data, but the SD was Ͻ5% in all cases.
Negative selection is inhibited in p35 transgenic mouse thymus To determine the requirement for caspase activation in antigenic peptide-driven negative selection in the thymic cortex, F5 TCR tg mice were crossed with the p35 animals, maintaining the H-2 b background. The F5 receptor utilizes (Mamalaki et al., 1993a) . In these mice, the majority of DP and CD8 ϩ SP thymocytes expressed the transgenic TCR (Mamalaki et al., 1993a) . F5 T-cell receptor (F5TCR)/p35 tg animals showed normal numbers of SP CD8 ϩ Vβ11 ϩ thymocytes ( Figure 6 , upper panels), and the p35 transgene did not affect the generation of mature CD8 ϩ Vβ11 ϩ lymphocytes (not shown). p35 expression thus did not affect positive selection triggered by the F5, MHC class I-restricted TCR.
To examine the sensitivity of p35 thymocytes to negative selection, F5TCR/p35 tg mice and F5TCR wild-type littermates received intraperitoneal (i.p.) injections of phosphate-buffered saline (PBS) (control) or the F5 antigenic peptide. Injection of this peptide results in early clonal deletion of immature DP thymocytes in the thymic cortex, as well as activation and expansion of mature T cells in the periphery in F5TCR animals (Mamalaki et al., 1993a,b) . Thymocytes and lymph node cells were isolated and stained with mAb to CD4, CD8, CD3, CD69, CD25 and Vβ11, and analyzed by flow cytometry. PBSinjected F5TCR/p35 tg mice showed the same T-cell subpopulation distribution as F5TCR littermates, with a predominance of SP CD8 ϩ Vβ11 ϩ cells over SP CD4 ϩ Vβ11 ϩ in the thymus (Figure 6 ) and lymph nodes (not shown), reflecting unaffected positive selection in these mice. F5TCR littermates receiving a single, high dose (75 nmol) of the F5 peptide showed a massive reduction in cell number (23% cell survival) in the thymus after 24 h ( Figure 6 ). All cell subpopulations decreased in absolute number, with the DP subpopulation the most affected (from 76 to 32%) (Mamalaki et al., 1992) . In contrast, in F5TCR/p35 tg mice receiving the same F5 peptide doses, this decrease in thymocyte number was inhibited (44% cell survival versus 23% in controls), and the proportion of DP thymocytes was also less affected (from 74 to 54%). Thymocyte activation was unaffected, since CD69 and CD25 activation marker expression after peptide injection were comparable in F5TCR and F5TCR/p35 animals (not shown). In experiments using lower F5 peptide doses (19 nmol), cell numbers were reduced tõ 50% in F5TCR tg mice, both in whole thymus and in the DP compartment, whereas cell number was unaffected in p35-expressing thymus ( Figure 7A ).
After an in vivo peptide challenge, we analyzed PARPproteolytic processing, a well characterized endogenous substrate of CPP32-like caspases. Thymocytes isolated from PBS-and peptide-injected mice were placed in culture medium and incubated at 37°C for 3 h; lysates of these thymocytes were subsequently immunoblotted to detect PARP. Freshly isolated thymocytes from peptideinjected mice contained no processed PARP, probably due to macrophage elimination of cells in apoptosis (Surh and Sprent, 1994; Alam et al., 1997 ; data not shown). In contrast, after 3 h culture, PARP cleavage occurred only in peptide-injected F5TCR animals, and this processing was inhibited in p35 thymocytes ( Figure 7B ). There was thus a correlation between inhibition of negative selection and the ability of p35 to inhibit PARP processing in thymocytes which were primed in vivo for apoptosis.
To further examine p35-expressing thymocytes for altered sensitivity to negative selection, we analyzed their deletion by the staphylococcal enterotoxin B (SEB) superantigen, which binds to class II molecules and to Vβ3, -7, -8 and -17 (White et al., 1989; Marrack and Kappler, 1990) . This binding leads to selective elimination of CD4 ϩ SP thymocytes expressing these Vβ, but also to deletion in the DP compartment when high-to-moderate doses of SEB are injected (White et al., 1989; Kishimoto et al., 1998) . In SEB-injected (25 μg, i.p.) control littermates, the total thymocyte number was reduced to 50%. In contrast, no reduction in total thymocyte number was seen in p35 tg mice treated in parallel ( Figure 8A ). Similar results were observed in the DP compartment ( Figure 8A ). The induction of the CD69 early activation marker on Vβ8 ϩ thymocytes from p35 tg animals was comparable with that in control littermates, supporting the specificity of the p35 transgene for the negative selection process (not shown). We also analyzed CPP32-like activity in thymocyte lysates from SEB-treated mice using a specific fluorogenic substrate (Wilhelm et al., 1998) . p35 expression caused a clear reduction in CPP32-like activation after SEB injection ( Figure 8B ), and PARP processing (A) Depletion of thymocyte subpopulations from control and p35 tg mice by SEB injection. Ten-week-old control or p35 tg mice on an H-2 b background received i.p. injections of PBS or SEB (25 μg) in PBS. After 24 h, thymocytes (10 6 ) were stained with tricolor-anti-CD8, FITC-anti-CD4 and biotin-anti-Vβ8 or Vβ6, followed by PE-conjugated streptavidin. The figure represents the total numbers of thymocytes and DP thymocytes in these mice. (B) After 24 h, thymocytes (4ϫ10 6 ) from PBS (control) or SEB-injected mice were lysed and extracts assayed for CPP32 caspase activity using a CPP32-like fluorogenic substrate as indicated in Materials and methods. (C) Proteolytic PARP processing in thymocytes from SEB superantigen-injected animals. Thymocytes from PBS-and SEBinjected animals were cultured at 37°C for 6 h to induce PARP processing in cells primed to apoptosis in vivo; cells were then lysed and the lysates electrophoresed. Substrate cleavage was visualized by immunoblotting as described in Materials and methods and Figure 7A. was also inhibited in p35 thymocytes cultured at 37°C for 6 h ( Figure 8C ). There was thus a correlation between the inhibitory effect of p35 on SEB-induced negative selection and its ability to interfere with CPP32-like activation in vivo.
Discussion
A large body of results suggests that caspases are activated during in vitro and in vivo thymocyte cell death (Sarin et al., 1996; Alam et al., 1997; Clayton et al., 1997) , demonstrating that caspase activation is associated with TCR-controlled apoptosis of thymocytes in vitro. Using a TCR transgenic model, Alam et al. (1997) showed that injection of an exogenous peptide induced CPP32 processing and PARP cleavage. The in vivo-primed CPP32 processing and activation was prevented in vitro by the caspase inhibitor Z-VAD-fmk; this inhibition correlated with in vitro blockage of apoptosis in thymocytes. These results were validated using FTOCs from a TCR tg mouse (Clayton et al., 1997) . Several attempts have been made to analyze the contribution of effector caspases to in vivo thymic negative selection, yet no definitive results have been reported. Caspase KO mice suggest functional redundancy among members of the effector (CPP32-like) caspase family (Kuida et al., 1996) ; thymocytes of CPP32 KO mice were thus as sensitive as control thymocytes to cell death induced by a wide variety of apoptosis inducers, including anti-TCR and anti-CD95 antibodies. In these experiments, functional compensation by other caspases of the same family was suggested, and the existence of CPP32-like PARP-cleaving activity was observed (Kuida et al., 1996) . In another approach, crmA, a viral inhibitor of caspases-1 and -8 which does not inhibit effector caspases, was expressed in thymus (Smith et al., 1996; Walsh et al., 1998) . While crmA expression inhibits in vitro CD95-mediated apoptosis, it does not affect negative selection driven by minor lymphocyte stimulating antigen (mls) or H-Y endogenous antigens. The effect of transgene expression on exogenous antigen-induced negative selection was not evaluated in these animals (Smith et al., 1996; Walsh et al., 1998) . crmA is an inhibitor of ICE-like caspases but does not interfere with CPP32-like caspases (Nicholson and Thornberry, 1997) , which are common executioners in cell death; this fact may underlie the observed lack of effect on negative selection. Attempts to drive transgenic expression of other heterologous caspase inhibitors, such as p35, may help to clarify these points.
To address the role of effector or executioner caspases on negative selection, we expressed a well-characterized, broad-range inhibitor of this protease family, baculovirus p35 (Bump et al., 1995; Ahmad et al., 1997; Zhou et al., 1998) . Previous work indicates that no single experimental system alone can serve as a definitive model of thymocyte negative selection (Foy et al., 1996; Page et al., 1998) . We therefore examined the role of p35 in two negative selection models, and found that MHC class II-restricted negative selection induced by SEB superantigen was indeed inhibited in p35 tg mice. Using SEB, thymocyte numbers in the DP compartment decreased to 50% in control littermates, whereas the decrease in p35 tg mice was minimal (Figure 8 ). These results correlated with the ability of p35 to inhibit in vivo-primed PARP processing and CPP32-like activity. Comparable observations were made when the transgenic F5TCR was used as a model for class I-restricted, antigen-specific, peptide-induced negative selection. We believe that the effects observed on cortical thymocytes after antigen injection are direct and not due to massive activation of mature T cells and subsequent release of cytokines or putative stress factors. In the F5 tg model, no effect was observed in the thymus of non-tg mice that received 10 8 F5 TCR transgenic spleen cells and were peptide-challenged the same day (Mamalaki et al., 1992) . In our experiments, Vβ8 ϩ , but not Vβ6 ϩ SP thymocytes were specifically eliminated following SEB injection. The possibility of a secondary effect thus appears unlikely. p35 expression inhibits negative selection in an antigen dose-dependent manner. Inhibition is also less efficient under conditions of massive apoptosis, probably due to a lack of inhibition of CPP32-like activity and PARP processing after in vivo challenge (M.Izquierdo, unpublished data). There are several possible explanations for these findings. First, inhibition of caspase activity depends on p35 expression, and the p35 expression level in these mice may be insufficient to completely block caspase activity. Secondly, activation of CPP32 family members may be dose dependent. By increasing peptide dose, it is conceivable that a member of this family with low activity under presumably physiological conditions (low antigen dose) could take over the activity of the inhibited executioner(s). There are examples in which the mediators and/ or executioners involved in negative selection may change, depending on the deleting antigen doses or the kinetics of the analyses used. This occurs in CD95-deficient mice, in which thymocyte elimination is CD95-independent at low antigen dose, but CD95-dependent at high doses (Kishimoto et al., 1998) , or when early thymocyte deletion (ഛ24 h) is analyzed (Castro et al., 1996) . It is also feasible that another caspase(s), which may not be a CPP32 family member but exhibits PARP-cleaving activity, takes part in thymocyte apoptosis under these conditions, since substrate redundancy has also been shown among caspase family members (Nagata, 1997) . A third possibility is that the residual thymocyte death observed in p35 tg mice is caused by a caspase not inhibitable by p35; in fact, spontaneous in vitro thymocyte cell death is not blocked in these mice. A caspase, different from CPP32 but displaying PARP-processing activity and inhibitable by the Z-VAD-fmk caspase inhibitor, must be implicated in spontaneous thymocyte apoptosis (Alam et al., 1997) . Our data strengthen this hypothesis by indicating that p35 inhibits CPP32-like activity and delays PARP processing, but is unable to inhibit spontaneous in vitro thymocyte death. This caspase does not belong to the CPP32-family, since we were unable to inhibit either spontaneous cell death or PARP processing in wild-type thymocytes using the CPP32-like specific inhibitor Ac-DEVD-CHO. Neither crmA (which inhibits caspases-1 and -8 in vitro) (Smith et al., 1996; Walsh et al., 1998) nor p35 (specific in vitro for caspases-1, -2, -3, -4, -6, -7, -8 and -10) affect spontaneous cell death when expressed in thymocytes. Single knockouts of caspases-1, -2 and -3 show no effect on spontaneous thymocyte cell death (Kuida et al., 1995 (Kuida et al., , 1996 Bergeron et al., 1998) . Assuming that p35 inhibits the same caspases in vivo, one or more of the remaining members of the caspase family (i.e. caspases-5 and -9) may therefore be responsible for this death; PARP-cleaving activity has been demonstrated only for caspase-9 (Nagata, 1997) . It has also been proposed that cytochrome c release from mitochondria and sequential activation of caspase-9 constitutes an alternative caspase-3 activation pathway in certain cell types (Li et al., 1997; Scaffidi et al., 1998) . In this model, bcl-2 interferes by blocking cytochrome c release from mitochondria, which would subsequently inhibit activation of caspase-9 and -3, while the 'classic' pathway for caspase-3 activation initiated by caspase-8 would remain intact (Scaffidi et al., 1998) . Both caspase-9 KO and bcl-2 tg thymocytes display similar resistance to Dex-and γ-irradiation, but are sensitive to anti-CD95 antibody (Smith et al., 1996; Hakem et al., 1998; Kuida et al., 1998) . This, and the relationship between caspase-9 and bcl-2, support the hypothesis that caspase-9 plays an important role in spontaneous thymocyte cell death and may also account for the remaining cell death observed in p35 tg mice. We are presently testing this possibility by making double tg mice expressing p35 and bcl-2.
Although unaffected positive selection, in conjunction with blocked negative selection, might be expected to give rise to increased thymocyte numbers, this was not the case in p35 tg mice. One explanation is that the overall negative selection inhibition in p35 tg mice may be undetectable due to the small fraction of thymocytes undergoing negative selection (Surh and Sprent, 1994; Sprent and Webb, 1995) , unless this thymocyte fraction is increased using superantigens or TCR-transgenic models. An alternative may be the inability of the p35 transgene to block negative selection following the use of large amounts of deleting antigen and/or chronic treatment with exogenous antigen (M.Izquierdo, unpublished results). Using p35 tg mice, we observed no inhibition of endogenous mls-driven negative selection, a process presumably sustained throughout thymic development (M.Izquierdo, unpublished results). It is noteworthy that endogenous mls-driven negative selection is a late-stage event occurring mainly in the thymic medulla, soon after maturation of the SP population (Marrack et al., 1993; Surh and Sprent, 1994; Sprent and Webb, 1995; Page et al., 1998) . In contrast, the deletion induced in F5TCR tg mice (Mamalaki et al., 1992) and that induced by highto-moderate SEB doses in adult animals (Kishimoto et al., 1998) provide models for studying negative selection in the thymic cortex (immature DP stage) (Page et al., 1998) , where p35 is expressed. The p56lck pr promoter is active mainly in immature thymocytes (Wildin et al., 1991) , and the vector used in our experiments triggers higher transgene expression levels in DP than in SP thymocytes (Sentman et al., 1991; Swan et al., 1995) . The lack of effect on negative selection in the mls model of p35 transgene may be due to its lower expression level in the SP thymic population, in which mls-driven negative selection occurs (Surh and Sprent, 1994) . Our inability to detect p35 transgene expression or apoptosis defects in T cell blasts from mitogen-responsive SP thymocytes supports this hypothesis.
Although cellular homologues of p35 have not yet been reported, a second caspase inhibitor gene product encoded by baculovirus, opIAP, has been described as a member of the inhibitor of apoptosis (IAP) family. Different human and murine IAP family members have been characterized, which inhibit several CPP32-like family members (caspase-3 and -7) (Deveraux et al., 1997 (Deveraux et al., , 1998 Tschopp et al., 1998) . Expression of the inhibitor transgenes opIAP, crmA, and the p35 broad-range caspase inhibitor reported here will help to clarify both the role of executioner caspases and the contribution of endogenous regulators to the negative selection process. In summary, our results demonstrate that, despite redundancy in effector caspases, p35 inhibits negative selection. Extending this approach, directing the expression of viral or cellular caspase inhibitors to various stages of lymphocyte differentiation may aid in elucidating the mechanisms of negative selection and their role in the maintenance of tolerance towards self.
Materials and methods

Generation of transgenic mice
Acp35 cDNA was removed from the pRM -35K-ORF plasmid (Hershberger et al., 1994) and subcloned into the BamHI site 3Ј of the p56lck pr 164 in the lck-human growth hormone (hGH) vector (Chaffin et al., 1990) . A 6.2 kb NotI fragment containing the T cell-specific regulatory elements, p35 cDNA and hGH poly(A) signals was purified and diluted in microinjection buffer (10 mM Tris pH 7.5, 0.12 mM EDTA; final concentration of 2 μg/ml). After filtration and centrifugation (15 000 g, 10 min, 4°C), this DNA solution was used for microinjections.
Fertilized oocytes from (C57BL/6ϫCBA)F 1 mice were isolated and pronuclei were injected with the DNA solution. Microinjected eggs were cultured in M16 medium drops at 37°C and 5% CO 2 for 20-24 h; eggs at the two-cell stage were transferred into the oviducts of recipient pseudopregnant OF1 females as described (Hogan et al., 1994) . Offspring were analyzed for the p35 gene 21 days after birth by PCR and Southern blot analysis.
Primers used to detect plck/p35 transgenic mice by PCR To detect plck/p35 tg mice we routinely used the hGH-3 (5Ј-GCACACG-CTGAGCTAGGTTCCC-3Ј) and hGH-4 (5Ј-CATAGACGTTGCTGTC-AGAGGC-3Ј) primers; these primers hybridize at the hGH region of the transgene construct. The amplified fragment is 415 bp long. We also used a primer set for thyroid-stimulating hormone β (TSHβ) gene as an internal control for the quality of the DNA preparation and PCR efficiency (Walter et al., 1989) , TSHβ-5Ј (5Ј-TCCTCAAAGATGCTCATTAG-3Ј) and TSHβ-3Ј(5Ј-GTAACTCACTCATGCA AAGT-3Ј). The amplified fragment is 386 bp long.
Mice p56lck pr p35 mice were initially typed by PCR screening using three different primer pairs specific for Acp35 and hGH elements, leading to the identification of 12 founder mice. Transgenic F 1 pups were detected by Southern blot hybridization and offspring inheriting the transgene were typed in a PCR strategy that identifies the hGH element of the construct. Internal (control) primers for endogenous TSHβ were used thereafter for PCR. Two transgene positive lines were backcrossed (Ͼ7 crosses) onto the C57BL/6 background for subsequent experiments.
For certain experiments, these heterozygous p56lck pr p35 tg mice were crossed with CBA/J mice (CRIFFA, Lyon, France) and typed for the p35 transgene as above. In other experiments, homozygous F5TCR tg mice on a C57BL/10 background (Mamalaki et al., 1992 ; kindly provided by Dr D.Kioussis, MRC, London, UK) were crossed with heterozygous p56lck pr p35 tg mice.
Southern blot analysis
Genomic DNA from tails of F 1 founder offspring was isolated with an Invitrogen Kit (San Diego, CA). Genomic DNA (10 μg) was digested with BamHI, separated in agarose gels and alkaline transferred to Zeta-probe membranes (Bio-Rad, Hercules, CA). The membrane was hybridized with a random-priming 32 P-labeled, full-length p35 cDNA probe (Southern, 1975) .
Cytosol preparation
After cell treatment with apoptosis inducers, all steps were performed at 4°C. Cells were sedimented (250 g, 10 min), washed twice in PBS and resuspended in extraction buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5 mM EDTA, 10 mM NaH 2 PO 4 , 1% Nonidet-P40, supplemented immediately before use with 0.4 mM Na 3 VO 4 , 1 mM phenylmethylsulphonyl fluoride, 10 μg/ml aprotinin and 10 μg/ml leupeptin). After 30 min incubation, the cell lysate was centrifuged (10 000 g, 30 min, 4°C) and the supernatant used as cytosolic extract.
Western blot analysis
Lysates of cells from tg and control mice were prepared as described above and size fractionated (25 μg per lane) by electrophoresis in 7% (for PARP immunoblotting) or 12.5% SDS-PAGE (for p35 immunoblotting). Western blotting was performed by standard methods using a p35 chicken polyclonal antibody (kindly provided by D.Niles, Promega, Madison, WI; 1:1000 dilution) and developed with horseradish peroxidase (HRP)-conjugated anti-chicken IgY (Promega, 1:1000 dilution). Alternatively, blots were probed with a monoclonal anti-PARP antibody (mAb) (Labgen, 1:300 dilution) followed by HRP-conjugated anti-mouse IgG antibody (DAKO, Glostrup, Denmark; 1:1000 dilution).
Flow cytometry
Cells from lymphoid organs of control and tg animals were disaggregated by mincing through a 10 μM nylon mesh to obtain single cell suspensions. For peripheral blood samples, erythrocytes were depleted by alkaline lysis with Quicklysis reagent (Cytogen). Cells were enumerated by trypan blue exclusion. For flow-cytometric analysis, cells were stained with saturating antibody concentrations at 4°C. Directly conjugated mAb used were against CD3-fluorescein isothiocyanate (FITC), CD4-(FITC), CD8-(tricolor), CD44-streptavidin-phycoerythrin (PE), CD25-(FITC), CD69-(FITC), CD95-(PE) (PharMingen, San Diego, CA and Southern Biotechnologies, Birmingham, AL). Anti-TCRVβ11, Vβ6, Vβ5, and Vβ8 were biotin-conjugated reagents (PharMingen) and were developed using streptavidin-phycoerythrin (PE) (Southern Biotechnologies) . Flow cytometry and multiparameter analysis were performed on a Coulter XL cytometer (Coulter, Miami, FL) . Dead cells were excluded by gating on forward and side light scatter.
Caspase assays
Cytosolic extracts (aliquots containing 1 mg/ml of cytosolic protein) were diluted 5-fold in assay buffer [25 mM HEPES pH 7.5, 0.1% CHAPS (w/v), 10% sucrose, 10 mM dithiothreitol and 0.1 mg/ml ovalbumin] and incubated (37°C, 2 h) with a 10 μM concentration of the fluorescent substrates [Ac-YVAD-AMC, AC-DEVD-AMC or Ac-VEID-AMC for ICE-, CPP32-and Mch2-like activity, respectively (AMC, 7-amino-4-methylcoumarin)]. The reactions were terminated by addition of HPLC buffer [H 2 O:acetonitrile (75:25), 0.1% trifluoroacetic acid]. Cleaved substrate fluorescence was determined by C18 reversephase HPLC using fluorescence detection (338 nm excitation, 455 nm emission). Control experiments confirmed that substrate release was linear with time and protein concentration under these conditions.
Tissue culture and cell-death assays
Cells from mouse tissues were cultured at 37°C in RPMI 1640 supplemented with 10% fetal calf serum, 10 μM mercaptoethanol, 100 mM L-glutamine, 10 mM HEPES, and antibiotics. Thymocytes (4ϫ10 6 cells/ ml) were cultured in 24-well plates in the absence (spontaneous cell death) or presence of different apoptosis inducers. Some wells were coated with anti-CD3ε antibody (2C11, 10 μg/ml overnight, then washed). Cell death was assayed at the indicated times after the initiation of culture. Cells with apparent DNA content Ͻ2n as determined by flowcytometric analysis of PI-stained samples (Coulter DNA-Prep) were considered apoptotic. The percentage of cell survival (percent diploid cells) in treated cultures was calculated relative to the percentage survival of parallel untreated cultures (spontaneous cell death). To examine activation-induced cell death in vitro, thymocytes or spleen cells (1ϫ10 6 cells/ml) were activated by incubating for 3 days with 5 μg/ml concanavalin A (ConA; Pharmacia, Uppsala, Sweden) or phorbol 12-myristate 13-acetate (PMA) (2 ng/ml) plus ionomycin (0.5 μg/ml), washed, then incubated for an additional 2-3 days in 10% conditioned medium containing IL-2. T-cell blasts (1ϫ10 6 /ml) were cultured with IL-2; some wells were precoated with anti-CD3ε antibody as above. Other cells were restimulated with ConA or irradiated with UV light (10 mJ/cm 2 ). In some experiments, cells were deprived of IL-2 to analyze death by growth factor deprivation. Cell death was assessed at the indicated time points by cell-cycle analysis of surviving cells (cells in G 0 /G 1 , S and M phases). In some experiments, the caspase inhibitors zVAD-fmk or AcDEVD-CHO were used.
Induction of apoptosis in vivo
For in vivo apoptosis experiments, 8-to 10-week-old mice were challenged with a single i.p. injection of PBS (control), staphylococcal enterotoxin B (SEB, 25-50 μg; Toxin Technology, Sarasota, FL) or F5 peptide {influenza virus A/NT/60/68 nucleoprotein residues 366-374, ASNENMDAM ]} in PBS (19-75 nmol). The oligopeptide was synthesized on an automated peptide synthesizer (AMS 422; Abimed, Langefeld, Germany). After 24 h, lymphoid organ cell suspensions were prepared as above. To analyze PARP processing, thymocytes were isolated and cultured for 3-6 h at 37°C as above.
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